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Dairy products are an important part of a nutritionally balanced diet as their constituents can affect the
human state of health. By inhibiting the angiotensin I-converting enzyme, the tripeptides Val-Pro-Pro,
Ile-Pro-Pro, and Leu-Pro-Pro can lower blood pressure. As these peptides are produced during fermen-
tation, they are found in various dairy products like cheese, yoghurt, etc., but except for cheese only little
is known about their content. To investigate how other dairy products contribute to a supply of these
antihypertensive peptides, we developed and validated a fast and sensitive assay for quantification of the
three tripeptides with LC-MS/MS combined with a simple protocol for extraction and SPE-purification
from yoghurt, curd, or other products. Finally, the entire method was successfully applied to survey
peptide concentrations in samples from local dairies and thus expands our awareness on the content of
antihypertensive peptides in our food.
© 2019 Elsevier Ltd. All rights reserved.1. Introduction
It is well known that diet strongly affects human health, and a
balanced diet is consideredmost beneficial as it provides us with all
essential nutrients. Milk and dairy products have always been a
vital part of a balanced diet. In a recent large multinational cohort
study, health-promoting effects of milk, yoghurt, and cheese have
been proven and an inverse association of consumptionwith risk of
major cardiovascular disease events and mortality has been
demonstrated (Dehghan et al., 2018).
Dairy products are a heterogeneous group of foods; they origi-
nate from different sources (cow, sheep, goat, etc.) and are pro-
cessed under various conditions (e.g., fermentation with different
bacterial cultures) that strongly influence their composition. Be-
sides proteins, fats, carbohydrates, minerals, vitamins, and other.
nutrients, milk and dairy products serve as a good source for
potentially bioactive substances such as short peptides (Korhonen
& Pihlanto, 2006). During fermentation of yoghurt or ripening of
cheese, lactic acid bacteria liberate short peptides that can be
divided based on their mode of action, among others, into antihy-
pertensive, antithrombotic, antioxidative, antimicrobial, antitumor,
antiobesity, mineral-binding and immunemodulatory (for a review
see: Sultan, Huma, Butt, Aleem, & Abbas, 2018).
The antihypertensive effect of these lacto-peptides is mostly
explained by angiotensin I-converting enzyme (ACE) inhibitory
activity (for review see: Sieber et al., 2010). Up to now, several
hundred peptides from dairy products with antihypertensive ef-
fects have been reported, of which valine-proline-proline (VPP),
isoleucine-proline-proline (IPP), and leucine-proline-proline (LPP)
are best studied (J€ak€al€a & Vapaatalo, 2010; Korhonen, 2009;
Lehtinen et al., 2010; Miralles, Amigo, & Recio, 2018; Nakamura
et al., 1995; Yamamoto & Takano, 1999). Administration of these
tripeptides has been shown to lower blood pressure in different
experimental models of hypertension (Ehlers et al., 2012; J€ak€al€a,
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and mildly hypertensive humans (Turpeinen, J€arvenp€a€a,
Kautiainen, Korpela, & Vapaatalo, 2013). In addition, long-term
ingestion of tripeptide-containing dairy products decreased arte-
rial stiffness in humans, which might also contribute to antihy-
pertensive effects (Hirota et al., 2007; Jauhiainen et al., 2010b). The
clinical trials conducted so far have been incorporated into eight
meta-analyses in which it has been found that antihypertensive
effects of lactopeptide consumption are more pronounced in Asian
compared with Caucasian populations (for review see: Siltari,
Vapaatalo, & Korpela, 2019).
Sour milk fermented with Lactobacillus helveticus or Saccharo-
myces cerevisiae is known to contain high amounts of these tri-
peptides (Nakamura et al., 1995) and several “functional foods” rich
in ACE-inhibiting peptides have been reported (Beltran-Barrientos,
Hernandez-Mendoza, Torres-Llanez, Gonzalez-Cordova, & Vallejo-
Cordoba, 2016). Furthermore, ACE-inhibiting potential has been
shown for different cheese extracts (Bernabucci, Catalani, Basirico,
Morera, & Nardone, 2014; Pripp, Sørensen, Stepamak, & Sørhaug,
2006; Sieber et al., 2010).
For identification of these peptides, liquid chromatography
together with high resolution mass spectrometry is commonly
used (Ha et al., 2015; Kunda et al., 2012; Rodríguez-Illera, Ferreira
Da Silva, Boom, & Janssen, 2015), whereas, for quantification of
the peptides in dairy products, HPLC-methods with UV-VIS-
detection (Eisele, Stressler, Kranz, & Fischer, 2012; Ferreira et al.,
2007) or detection with mass spectrometry (Bütikofer, Meyer,
Sieber, Walther, & Wechsler, 2008; Bütikofer, Meyer, Sieber, &
Wechsler, 2007; Gonzalez-Gonzalez, Gibson, & Jauregi, 2013)
have been reported. Apart from these studies, in which IPP and VPP
content was examined in cheeses from mostly Swiss origin and
milk fermented with L. helveticus, only little is known about IPP,
VPP, and LPP content in other dairy products, e.g., yoghurt.
The applicability of the above described methods for investi-
gation of peptide content in other dairy products is limited. In
particular, methods with UV-VIS-detection lack selectivity and
suffer from coeluting substances that falsify quantitative data
(Rodríguez-Illera et al., 2015). Other methods require derivatisation
(Eisele et al., 2012), MS3-fragmentation (Bütikofer et al., 2007), or
high resolution MS-detection, and many reported methods are
based on excessively long chromatographic separation times
(Bütikofer et al., 2007; Eisele et al., 2012; Ferreira et al., 2007;
Gonzalez-Gonzalez et al., 2013; Kunda et al., 2012; Rodríguez-
Illera et al., 2015; van Platerink, Janssen, Horsten, & Haverkamp,
2006) that do not allow for high through-put analysis of multiple
samples. Additionally, peptides are only extracted from the
respective dairy products and, apart from the work of van Platerink
et al. (2006) in human plasma, analytes are not further purified.
Thus salts, other soluble proteins, or lipophilic components might
interfere with the mass spectrometric measurement, lead tomatrix
effects and ion suppression, or contaminate the sensitive instru-
ment, leading to loss of sensitivity.
Therefore, a fast and simple state of the art method is required in
which sample preparation and selective purification facilitates
sensitive and reliable quantification to expand our knowledge on
content of ACE-inhibiting tripeptides in different dairy products.
2. Materials and methods
2.1. Chemicals, standard compounds, and samples
The peptides VPP, IPP, and LPP (purity >99%) were purchased
form Bachem (Bubendorf, Switzerland), and the stable isotopically
labelled peptides V*PP, I*PP, and L*PP (purity >99%) with uniformly13C and 15N labelled Leu, Ile, and Val were purchased from PepScan
Presto (Lelystad, The Netherlands). LC-MS grade acetonitrile and
trifluoracetic acid (TFA) were purchased from Merck (Darmstadt,
Germany), LC-MS grade formic acid was purchased form VWR
(Vienna, Austria), and ultrapure water was prepared on site using
an Arium 611 UV from Sartorius (G€ottingen, Germany). Nitrogen for
mass spectrometry was produced on site by a PeakScientific In-
struments nitrogen generator (Inchinnan, UK) and the collision gas
argon (purity 99.999%) was purchased from Messer (Vomp,
Austria).
Three yoghurts (natural, strawberry, and apricot) from three
different dairy companies were used for method development and
validation. Applicability of the method for quantification in other
dairy products was demonstrated using a sour cream and a curd
sample. Furthermore, thirty yoghurt, six curd, five sour cream,
three creme fraîche, three sour milk, and two kefir samples from
thirteen dairy companies were investigated to assess influences of
flavour, nutrient content, special bacterial cultures, organic milk, or
special features. Nutritional data for each sample are summarised
in Supplementary material Table S1. All products were bought in
local supermarkets and stored at 4 C until processing. Each sample
was prepared and analysed in triplicate.
2.2. Sample preparation
Dairy product sample aliquots of 500 mg were diluted with
1.0 mL water containing 100 ng mL1 of each isotopically labelled
peptide and extracted by shaking 1400 rounds min1 at 40 C for
1 h in an Eppendorf thermomixer comfort (Hamburg, Germany).
After cooling to ambient temperature, solids were sedimented by
centrifugation for 20 min at 10,600 g in an Eppendorf 5804 R
centrifuge (Hamburg, Germany). From the clear solution between
pellet and lipid layer, 980 mL were taken and 20 mL TFAwere added.
After brief vortex mixing, the samples were again centrifuged for
5 min. The supernatants were transferred to Oasis® HLB Prime 3 cc
(60 mg) solid phase extraction (SPE) cartridges (Waters, Milford,
MA, USA) preconditioned with 1.0 mL acetonitrile and 1.0 mL
water þ 0.1% TFA. The extracts were slowly sucked through the
cartridge under reduced pressure. Afterwards, the cartridges were
washed with 1.0 mL water þ0.1% TFA and the peptides eluted with
1.0 mL of 70% acetonitrile in water. The eluates were dried under a
stream of nitrogen using a Biotage TurboVap LP nitrogen evapo-
rator (Uppsala, Sweden). The dry residues were reconstituted in
500 mL water by brief vortex mixing, transferred to glass auto-
sampler vials, and analysed by LC-MS/MS.
2.3. HPLC conditions
For HPLC analyses an Acquity UPLC (Waters) was used consist-
ing of a binary solvent manager, a sample manager cooled to 15 C,
and a column oven heated to 70 C. Every sample was analysed in
triplicate with an injection volume of 15 mL. As stationary phase a
Zorbax Eclipse XDB C18 100  3 mm, 3.5 mm column (Agilent,
Waldbronn, Germany) with a 4  2 mm C18 SecurityGuard guard-
cartridge (Phenomenex, Aschaffenburg, Germany) was used. The
mobile phase consisted of (A) water þ 0.1% formic acid and (B)
acetonitrile; composition of the linear gradient is given in Table 1.
The HPLC retention times of the peptides were 4.32 min (VPP),
5.72 min (IPP), and 6.51 min (LPP).
2.4. MS/MS conditions
For detection of the tripeptides, a XEVO TQD triple-quad mass
spectrometer (Waters) was used. The flow from the HPLC was
diverted to the source from minute 3 to 8 and for the remaining
Table 1
Composition and flowrate of the mobile phase for HPLC separation of VPP, IPP, and
LPP.a
Time (min) A (%) B (%) Flowrate (mL min1)
0 98 2 0.3
2 98 2 0.3
2.01 95 5 0.3
4 95 5 0.3
8 88 12 0.3
8.2 5 95 0.5
13 5 95 0.5
13.2 98 2 0.5
20 98 2 0.5
a A, water þ 0.1% formic acid; B, acetonitrile.
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cone voltage of 30 V were applied throughout the entire run time.
Nitrogenwas used as desolvation gas at a flowrate of 750 L h1 and
a desolvation temperature of 450 C, Argon was used as collision
gas. The MS/MS parameters are given in Table 2. Data were auto-
matically processed using TargetLynx software (Waters).2.5. Preparation of stock- and spiking solutions and method
validation
Three stock solutions of each unlabelled peptide were prepared
by weighing 1.0 mg of the peptide and dilute it with water to
concentrations of 1.0 mg mL1. The individual solutions were
combined to three mixed stock solutions with concentrations of
0.1 mg mL1 each. Spiking solutions with the desired concentra-
tions were prepared from the stock solution by serial dilution. The
calibration curve was prepared from two stock solutions and the
third stock solution was used for assessment of precision and
accuracy.
From the isotopically labelled peptides, 1.0 mg each were
weighed and diluted with water to a concentration of 1.0 mg mL1.
The individual solutions were combined and the extraction solu-
tion with a concentration of 100 ng mL1 was prepared by serial
dilution.
Method validation was carried out according to ICH guidelines
(ICH, 2006). Matrix-free calibrations were prepared by serial dilu-
tion of the unlabelled peptides in pure solvent. These solutions
were analysed without any further sample preparation. Matrix
matched calibration curves were obtained by spiking 500 mg of
yoghurt sample with amounts of 0, 5, 10, 25, 50, 75, 100, 250, 500,
and 1000 ng of unlabelled peptide. Samples were extracted, puri-
fied, and measured as described in section 2.2. The peptideTable 2
MS/MS parameters for quantification of VPP, IPP, and LPP, as well as the isotopically
labelled internal standards V*PP, I*PP, and L*PP.a
Peptide Precursor
ion (m/z)
Daughter
ions (m/z)
Collision
energy (eV)
Dwell
time (s)
VPP 312.1 69.9 30 0.497
197.1 12
213.1 16
IPP 326.2 69.9 30 0.497
211.1 12
213.1 16
LPP 326.2 69.9 30 0.497
211.1 12
213.1 16
V*PP 318.4 213.1 16 0.497
I*PP 333.1 213.1 16 0.497
L*PP 333.1 213.1 16 0.497
a Daughter ion traces used for quantification are bold.concentration of blank yoghurt was determined by standard
addition method and the calibration curves were adjusted
accordingly.
For assessment of stability, two samples containing amounts of
1000.0 ng mL1 of each of the 3 tripeptides and 100.0 ng mL1 of
the isotopically labelled analogues in the final solution were pre-
pared as described above. One sample was stored in the autosam-
pler at 15 C and the second one in a fridge at 4 C. Both samples
were measured in triplicate at day 0 and again after 10 days. The
concentrations were determined with the calibration curve and
results were calculated as percentage recovery of the initial
concentration.
Precision and accuracy were assessed by spiking amounts of 0,
25, 100, and 500 ng peptide to 500 mg yoghurt. Three whole milk
yoghurts (natural, apricot and strawberry flavoured) from three
different dairy companies were used. Intra- and inter-assay preci-
sion and accuracy were determined by preparation and measure-
ment of the samples on three different days. For assessment of
method robustness, samples and mobile phases were prepared by
two different operators. Precision is expressed as coefficient of
variation and accuracy as percentage of recovery of the nominal
concentration. Intra-assay precision and accuracy are expressed as
mean values of the three different yoghurts prepared on one day
and inter-assay precision and accuracy accordingly as mean of all
determinations on three days.
To prove applicability of the method to other dairy products,
curd and sour cream were used as examples; 500 mg of the
respective product were spiked with 0, 25, 100, or 500 ng each of
the three tripeptides and samples were prepared and analysed as
described above. Sensitivity of the measurement, completeness of
extraction, binding to and elution from the SPE-cartridges, as well
as intra- and inter-assay precision and accuracy of the measure-
ment, were assessed for these matrices in the same way as
described above for yoghurt.
3. Results and discussion
3.1. Optimisation of extraction and SPE purification
For extraction of water-soluble peptides from dairy products, a
protocol similar to the one proposed for cheese by Kuchroo and Fox
(1982) is commonly applied. It can also be used for other dairy
products, e.g., yoghurt (Papadimitrou et al., 2007) andwas thus also
chosen in this study. After diluting the samples of dairy products
with water in a ratio of 1:2 (w/v), they were extracted for 1 h at
40 C. In our study, we used a thermomixer as it allows enhanced
extraction of the samples at a constant temperature and shaking
speed that can be easily reproduced in different batches. We have
verified a high extraction yield by a subsequent second extraction
of the same samples and analysing each extract individually; in the
second extract, less than 7% of analyte were detected and the ma-
jority of the peptide was regained within the first extract. Thus,
preparation of a singular aqueous extract with a two-fold volume of
water at defined temperature and shaking speed followed by
centrifugation was considered appropriate and was therefore used
for all further analyses.
Apart from traces of the desired peptides, aqueous extracts of
dairy products contain mainly salts, carbohydrates, other soluble
proteins, free amino acids, organic acids like lactic acid, vitamins,
and, to some extent, lipophilic components (Salles, Septier, Roudot-
Algaron, Guillot, & Etievant, 1995). Thus, purification of the pep-
tides is preferable to reduce interference and matrix effects during
measurement, such as ion yield attenuation. Additionally, this
protects the highly sensitive mass spectrometer and chromato-
graphic columns from pollution and prevents loss of sensitivity or
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purification as their selectivity can be tailored to the analytes of
interest, and sensitivity of subsequent measurement can be
enhanced by enrichment of low-concentration analytes.
Due to the zwitterionic nature of all peptides, purification of
VPP, IPP, and LPP using (both cation and anion) ion-exchange SPE
cartridges was attempted at the beginning of this study. Excellent
results were obtained for samples with low salt concentrations.
However, we observed impaired binding of the peptides to the solid
phase with increasing amounts of salt in the sample; the peptides
were washed from the cartridge and consequently their recovery
was too low and irreproducible. The approach of using ion-
exchange SPE for purification of these tripeptides from dairy
products is therefore not advisable, as an unpredictable loss of
analyte during sample preparation due to additional substances
cannot be entirely excluded.
Using the hydrophilic-lipophilic balanced (HLB) copolymer
Oasis® HLB as sorbent for SPE purification circumvents this prob-
lem. In our trials, the highly polar peptides were completely
retained, and no breakthrough of peptide during loading or
washing of the cartridges was observed, even in samples with
extreme salt or fat content, and still a great deal of interfering
compounds were removed by this approach. Furthermore, using
higher volumes (larger than 1 mL) or repeated elution did not
improve peptide recovery, demonstrating exhaustive elution of the
peptides under the given conditions.
Care has to be taken when samples with high peptide contents
such as cheese are extracted and purified. For purification of
yoghurt samples, we used cartridges with only 60 mg sorbent, and
accordingly a low binding capacity. At too high quantities of matrix
components, the low sorbent amount is not sufficient for retaining
all analyte molecules and a breakthrough of the desired peptides
during loading or washing of the SPE cartridges might be observed.
Thus, it has to be evaluated carefully whether binding capacity is
sufficient for purification from the particular dairy product. Taking
this into account, sample preparation with Oasis® HLB SPE car-
tridges is a suitable method for purification of VPP, LPP, and IPP
from aqueous extracts of dairy product and therefor our method of
choice.
3.2. HPLC-method development
Chromatographic separation of proline-rich peptides, like VPP,
IPP and LPP, is a demanding task as these peptides elute from
common reversed-phase columns in broad peaks with poor shape
due to slow cis-trans-isomerisation of the Pro-Pro amide bonds
(Gesquiere, Diesis, Cung, & Tartar, 1989; Jacobson, Melander,
Vaisnys, & Horvath, 1984). In the course of our method develop-
ment, we used various stationary phases and different mobile
phase additives without affecting peak shape. Only on increasing
column temperature to 70 C were peak widths reduced signifi-
cantly and could reasonable resolution be achieved. Other than at
temperatures below 50 C, at which IPP and LPP co-elute and peaks
are split, elevated temperatures accelerate isomerisation, narrow
peaks, reduce tailing and splitting, and consequently lead to sepa-
ration of the two peaks.
As the tripeptides VPP, IPP, and LPP are quite small and polar,
they are poorly retained on C18-columns and are eluted with high
proportions of water in the mobile phase. Isocratic solvent
composition at the beginning of the chromatographic run is
necessary for separation of IPP and LPP, but it is accompanied by
broadening of the VPP peak. Thus, a reasonable compromise had to
be found between separation of the peaks and their width; this was
isocratic elution for 2 min followed by a quick increase of theproportion of organic modifier in the mobile phase, which led to
best peak shape of VPP. After a second isocratic separation, the
peptides IPP and LPP are eluted with a gentle gradient to obtain
optimum resolution. As IPP and LPP are position isomers with the
same molecular weight and similar fragmentation pattern, chro-
matographic separation is essential and the only way to differen-
tiate between the two peptides and determine their correct
concentrations. A terminal washing step with high proportions of
organic solvent at the end of the method is required to wash all
retained molecules from the column and prevent de-wetting of the
phase, which leads to shifting retention times.
The optimised gradient allows separation of VPP, IPP and, LPP
with best peak shape and peak resolution on a common HPLC
system in less than 8 min (Table 1). We have consciously chosen an
HPLC and not an UHPLC column but focused on the optimisation of
the gradient nonetheless facilitating a fast separation. Our inten-
sion was to provide a method suitable for high sample throughput
without the need for sophisticated instrumentation. The time
required for an analysis, however, can be further reduced by using
UHPLC columns.
3.3. MS method
Multiple reaction monitoring (MRM) is state of the art for MS/
MS quantifications due to its ability to eliminate interferences of co-
eluting substances by selecting the ions with the m/z of interest,
fragmenting them and select one or few specific fragment ions for
identification and quantification (van den Broek, Sparidans,
Schellens, & Beijnen, 2008). For development of our MRM-
method, pure peptides were infused via a syringe pump com-
bined with a LC flow into themass spectrometer. The measuredm/z
of the precursor ion was selected and all MS, and MS/MS parame-
ters were optimised individually for each peptide and their isoto-
pically labelled analogues. The optimum parameters are given in
Table 2. As peptides commonly fragment close to the amide bond,
the detected fragment ions could be assigned to amino acid resi-
dues easily. From the identified fragments, the precursor-daughter-
transition with highest signal intensity of the daughter ion was
chosen as the quantification trace, whereas two additional qualifier
fragment ions were selected for verification of peptide identity.
With the quantifier and two qualifier transitions as well as the
corresponding ion ratios, a high level of certainty of correct iden-
tification of the peptides is achieved. Especially for LPP and IPP,
which exhibit the same molecular mass and fragment ions, correct
and reliable identification is required and qualifier ions together
with their ion ratios can be used to verify annotation even in case of
retention time shifts.
As ESI ionisation is highly susceptible to matrix effects and ion
yield attenuation, the use of internal standards, preferably stable
isotopically labelled ones, is strongly recommended in all MS an-
alyses. Various isotopically labelled amino acids, usually uniformly
13C- and 15N-labelled, are available for synthesis of labelled pep-
tides. Labelled compounds exhibit the same physico-chemical
properties as their unlabelled equivalents. When added at the
beginning of an analytical workflow, the ratio between labelled and
unlabelled peptide stays the same throughout the entire sample
preparation andmeasurement. Thus, minor losses of analyte during
sample preparation, as well as ionisation effects during measure-
ment, such as ion suppression or other matrix effects, can be
balanced out (van den Broek et al., 2008). By using isotopically
labelled internal standards, we could improve repeatability, accu-
racy, and precision of the entire analysis and for instance, co-
efficients of variation of repeated analysis of an individual sample
could be reduced from ~14 to ~2 for VPP and IPP.
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Validation of above described sample preparation and mea-
surement methods has been performed by spiking known amounts
of the three tripeptides to yoghurt samples from different local
dairies with different flavours, namely natural yoghurt, strawberry,
and apricot, to minimise bias of manufacturing processes or addi-
tives such as fruit, aroma, and colourants. Calibration curves were
prepared only in the apricot yoghurt whereas precision and accu-
racy were assessed in all three yoghurts. Calibration curves were
obtained by linear regression of the response values and the cor-
responding concentration. The linear range was assessed in the
range of 10.0e2000.0 ng g1 and, for the entire range, correlation
coefficients, R2, of >0.99 were obtained. In addition to the matrix
matched calibration, a calibration curve in purewater was prepared
to assess limits of detection (LOD), limits of quantification (LOQ),
and matrix effects. LOD and LOQ were calculated by dividing 3.3-
times (LOD) or 10-times (LOQ) the standard deviation of the
response of blank samples by the slope of the calibration curve. In
this way, LOD between 0.9 and 3.0 ng g1 and LOQ between 2.6 and
9.0 ng g1 were obtained (see Table 3). Comparison of the slopes of
matrix matched calibration and calibration in pure water revealed
differences in slope less than 1.5% for IPP and LPP and 5.3% for VPP.
Thus, for IPP and LPP, the peptide extraction can be considered
quantitative and, for VPP, only a negligibly small proportion re-
mains unextracted in the matrix or is lost during sample
preparation.
For determination of carry-over, blank samples were analysed
directlyafter spikedsampleswithhighconcentrations (2000.0ngg1)
of peptide. As no detectable traces of the peptides were found in the
blanks, a distortion of analyses by carry-over between consecutively
analysed samples can be excluded.
Sample stability was assessed in two spiked samples with a final
peptide concentration of 1000.0 ng mL1. After preparation
following the above described protocol, the samples were analysed
with LC-MS. Subsequently, they were stored for 10 days, one in the
autosampler at 15 C and the other one at 4 C, before they were
analysed again, and the findings of the analysis before and after
storage were compared. The percentage recoveries of the initial
concentration are given in Table 4. For all tripeptides after 10 days
of storage under both conditions, recoveries close to 100% within
the limits of precision and accuracy were achieved. Thus, it can beTable 3
Linear range, regression function, correlation coefficient, LOD, and LOQ for quantification
Peptide Linear range (ng g1) Regression equation
VPP 10e2000 y ¼ 1.0310x þ 1.1112
IPP 10e2000 y ¼ 1.6177x þ 6.0777
LPP 10e2000 y ¼ 1.5752xe2.9873
Table 4
Results for validation of assay precision and accuracy using three yoghurts from three ma
temperatures over ten days.
Peptide Spiked amount (ng g1) Precision (%)
Assay Inter-da
1 2 3
VPP 50.0 4.0 5.2 4.7 5.1
200.0 5.0 4.4 3.1 5.8
1000.0 3.4 4.6 4.9 4.3
IPP 50.0 3.3 4.3 2.4 5.2
200.0 4.2 4.9 6.4 4.9
1000.0 3.7 4.5 4.3 4.1
LPP 50.0 5.7 3.7 4.3 7.6
200.0 3.9 6.2 5.1 5.4
1000.0 9.1 3.9 4.6 3.2assumed that storage of the solutions under the tested conditions
does not negatively affect the outcome of the analyses.
Accuracy and precision of the assay were determined in spiking
experiments with amounts of 25, 100, and 500 ng of the three
peptides in 500 mg yoghurt. Accuracy and precision have been
calculated independently for the individual (intra-assay) as well as
all over the assays (inter-assay). The results are summarised in
Table 4. The entire method validation, including weighing of stan-
dards, sample extraction, SPE purification, and preparation of mo-
bile phases, etc. was conducted independently by two operators
several times and equivalent results were obtained throughout.
Reasonably low coefficients of variation (i.e., precision) were ob-
tained for the individual assays as well as overall assays. Together
with the recovery results (i.e., accuracy), which on average are close
to 100% for the three tripeptides in all assays, validation results
prove the entire method to be sensitive, reproducible, and accurate
as well as robust and unsusceptible to minor inaccuracies.
Taken together, during method validation we showed that the
sample preparation protocol is capable of effectively removing
interfering components, while the peptides of interest can be
quantified accurately even in low concentrations.
3.5. Applicability of the method for other dairy products
To verify the applicability of the developed method not only for
yoghurt but also for other fermented dairy products, curd and sour
cream were taken as examples. Cheese samples were left out
because the tripeptide content of several cheeses was investigated
previously by others (Bütikofer et al., 2007; 2008). As it could be
shown for yoghurt that calibration in pure solvent and matrix-
matched calibration gave comparable results, no additional
matrix-matched calibration was prepared for the new matrices.
The calibration curve, prepared for yoghurt, was used for deter-
mination of recovery and precision in these dairy products. Re-
covery and precision were determined in the same way as
described for yoghurt; peptide amounts of 50, 200, and 1000 ng g1
dairy product were spiked and samples were prepared and
measured on two consecutive days according to the above
described protocol.
The results for all three peptides were comparable to the
method validation for yoghurt; in curd, a mean coefficient of
variation of 7.3% (range: 4.7%e9.9%) with a mean recovery ofof VPP, IPP, and LPP in yoghurt samples.
R2 LOD (ng g1) LOQ (ng g1)
0.9974 0.9 2.6
0.9956 3.0 9.0
0.9927 1.6 4.9
nufacturers as well as sample stability assessment in spiked yoghurt samples at two
Accuracy (%) Stability (%)
y Assay Inter-day 4 C 15 C
1 2 3
98.4 113.5 91.3 101.1 105.7 95.4
93.3 102.6 105.8 97.8
87.3 101.3 105.5 96.3
102.5 99.9 99.3 106.5 101.6 101.3
89.8 93.8 92.3 97.4
91.6 97.3 94.6 98.9
103.0 103.6 96.3 101.1 96.7 105.9
103.9 88.6 89.5 97.8
96.9 87.8 88.6 96.3
Table 5
Contents of VPP, IPP, and LPP in fermented dairy products investigated in this study.a
Sample VPP (ng g1) IPP (ng g1) Ratio
Mean SD Mean SD VPP/IPP
Yoghurts
yoghurt 1 40.8 3.4 DNQ e
yoghurt 2 39.5 1.0 DNQ e
yoghurt 3 78.3 8.3 13.3 1.4 5.9
yoghurt 4 67.4 1.6 23.4 3.6 2.9
yoghurt 5 16.8 1.1 ND e
yoghurt 6 53.9 2.2 DNQ e
yoghurt 7 64.7 9.7 27.1 2.8 2.4
yoghurt 8 62.1 6.5 28.7 5.1 2.2
yoghurt 9 111.4 6.6 39.1 2.8 2.9
yoghurt 10 70.6 4.2 48.5 4.0 1.5
yoghurt 11 154.0 5.0 75.1 2.1 2.1
yoghurt 12 187.6 5.8 134.7 22.2 1.4
yoghurt 13 44.3 1.2 11.3 2.2 3.9
yoghurt 14 67.9 1.3 30.9 1.6 2.2
yoghurt 15 111.0 16.7 66.5 6.6 1.7
yoghurt 16 38.3 5.8 14.0 4.9 2.7
yoghurt 17 270.2 2.4 115.1 0.8 2.4
yoghurt 18 284.6 4.6 121.9 1.9 2.3
yoghurt 19 80.3 1.5 11.1 0.4 7.2
yoghurt 20 27.3 0.6 DNQ e
yoghurt 21 51.3 0.2 12.4 0.3 4.2
yoghurt 22 12.7 0.3 ND e
yoghurt 23 544.6 8.0 165.0 0.7 3.3
yoghurt 24 455.1 9.9 119.2 0.4 3.8
yoghurt 25 123.0 4.9 37.6 0.4 3.3
yoghurt 26 118.6 2.2 31.5 0.2 3.8
yoghurt 27 121.2 3.5 34.5 0.6 3.5
yoghurt 28 158.7 3.4 49.5 0.9 3.2
yoghurt 29 45.6 4.1 DNQ e
yoghurt 30 40.5 2.8 14.8 2.8 2.7
Sample VPP (ng g1) IPP (ng g1) LPP (ng g1) Ratio
Mean SD Mean SD Mean SD VPP/IPP
Sour milk
sour milk 1 156.8 3.0 17.3 0.3 ND 9.1
sour milk 2 470.1 20.5 67.7 1.6 ND 7.0
sour milk 3 34.8 1.7 DNQ ND e
Kefir
kefir 1 129.0 3.7 10.5 0.3 ND 12.3
kefir 2 365.5 21.6 80.1 1.3 ND 4.6
Creme fraîche
creme fraîche 1 333.6 2.2 68.7 0.2 ND 4.9
creme fraîche 2 243.2 2.6 14.6 0.3 ND 16.7
creme fraîche 3 353.3 12.9 45.9 1.7 ND 7.7
Sour cream
sour cream 1 149.9 5.8 20.0 1.0 ND 7.5
sour cream 2 259.8 14.0 33.0 0.8 ND 7.9
sour cream 3 260.4 15.3 38.8 1.1 ND 6.7
sour cream 4 264.7 14.8 25.6 0.5 ND 10.3
sour cream 5 262.5 5.4 43.1 2.6 ND 6.1
Curd
curd 1 341.9 5.1 66.0 0.8 6.3 5.2
curd 2 206.9 0.5 51.6 2.3 DNQ 4.0
curd 3 210.3 2.0 46.8 1.6 DNQ 4.5
curd 4 238.9 4.7 49.0 0.7 DNQ 4.9
curd 5 381.7 7.4 149.8 0.9 ND 2.6
curd 6 266.7 3.1 109.3 1.4 ND 2.4
a Every sample was prepared and analysed in triplicate: SD, standard deviation; DNQ, detected but not quantified (below LOQ); ND, not detected.
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ficient of variation of 9.4% (range: 5.8%e12.1%) with a mean
recovery of 101.9% (range: 88.5%e110.7%) were obtained. As the
results for yoghurt, curd, and sour cream meet the acceptance
criteria of the ICH guideline (ICH, 2006) we suppose that the
sample preparation and measurement methods are applicable
not only for yoghurt but also for other fermented dairy
products.3.6. Results from quantification of peptides in different dairy
products
The validated method has subsequently been used for investi-
gation of different dairy products of (predominantly) local origin;
thirty yoghurt, six curd, five sour cream, three creme fraîche, three
sour milk and two kefir samples were selected for detailed inves-
tigation of VPP, IPP, and LPP content. It is well known that formation
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Fig. 1. Concentrations of VPP plotted against concentrations of IPP in yoghurt ( ), sour
milk and kefir ( ), sour cream and creme fraîche ( ), and curd ( ) samples inves-
tigated in this study.
S. Moosmang et al. / International Dairy Journal 97 (2019) 31e39 37of these peptides is strongly dependent on various factors, such as
cultures used for fermentation, ripening times, andmore (Bütikofer
et al., 2008; Fuglsang, Nilsson, & Nyborg, 2002; Yamamoto, Akino,
& Takano, 1994). Accordingly, remarkable differences between
samples were observed. The results of all forty-nine investigated
products are summarised in Table 5.
Other than in most previously published studies on quantifica-
tion of antihypertensive peptides, only van Platerink et al. (2006)
and Eisele et al. (2012) included LPP into their methods. There-
fore, little is known about LPP content in dairy products. As it is a
known ACE inhibitor (Lehtinen et al., 2010), in our opinion, LPP
should not be disregarded in such investigations, and therefore, it
was also incorporated in our trial. However, LPP was detected only
in 4 curd samples and exceeded LOQ in only one. In all other
samples examined, LPP could not be detected, as it was not pro-
duced in sufficient amounts under the respective fermentation
conditions. In the work of Eisele et al. (2012), LPP was detected in
Evolus® milk in lower amounts than VPP or IPP, but still higher
(0.8 mg mL1) than in the present work. Therefore, despite the low
concentrations detected, LPP should be investigated in future
studies to explore the content in other products and to potentially
find conditions for enhanced formation.
Concentrations of IPP were below LOD in both investigated
Greek-style yoghurts and below LOQ in five further yoghurt and
one sour milk sample. In all other samples, IPP could be quantified
with amounts ranging from LOQ to 165 ng g1 with a mean con-
centration of 45 ng g1 and a median of 33 ng g1. On the other
hand, VPP was detected in all samples and in higher amounts than
the other two peptides in a range of 12e544 ng g1 with a mean of
173 ng g1 and a median of 128 ng g1. However, the investigated
types of dairy product and samples from various manufacturers
differ in mean peptide content and ratios of VPP/IPP (Fig. 1), which
presumably results from differences in production conditions.
Hence, a clear classification of the investigated dairy products ac-
cording to either peptide content or ratio of VPP/IPP from the
present data is not possible. However, a trend towards relative
accumulation of VPP was observed in curd, sour cream, creme
fraîche, sour milk and kefir, whereas, in yoghurt, higher relative
proportions of IPP were observed.
The highest differences in content of VPP and IPP between
samples were observed in yoghurt samples. In particular, the
Greek-style yoghurts investigated contained only low amounts of
VPP, whereas IPP could not even be detected. On the other hand,
highest contents (VPP, 270e544 ng g1; LPP, 115e165 ng g1) were
observed in samples fermented with Lactobacillus acidophilus and
Bifidobacterium sp. The fact that samples fermented solely with
Bifidobacterium sp. exhibit lower peptide concentrations suggest
that fermentationwith L. acidophilus is responsible for an increased
liberation of VPP and IPP in the respective products. Apart from
samples containing L. acidophilus and Bifidobacterium sp., no in-
formation on cultures or production processes was available and
thus cannot be discussed here.
Unsurprisingly, a strong positive correlation (correlation coef-
ficient ~0.75) between protein content and detected amounts of
VPP and IPPwas observed in all yoghurt samples from a single dairy
(n ¼ 10, dairy e), as the peptides are liberated from proteins. On the
other hand, in these samples a strong negative correlation (corre-
lation coefficient ~ 0.80) was observed between peptide and fat
content. Peptide content and other ingredients like salt, carbohy-
drates, or sugar gave only weak negative correlations (correlation
coefficient between 0 and e0.5), which do not suggest an impact of
these factors. Furthermore, no clear correlations are observed be-
tween flavour, lactose free, or organic yoghurt and peptide content.
These findings are confirmed by comparable results in five yoghurt
samples from dairy f.However, when all yoghurt samples investigated in this study
are considered, correlations between VPP or IPP content and fat or
protein are less distinct (~e0.5 between fat and peptide or ~ 0.1
between protein and peptide content) than for products of an in-
dividual dairy. This presumably has to be attributed to differences
in raw material, fermentation processes, and fermentation condi-
tions between the dairies.
The dairy products investigated in this study contain the tri-
peptides VPP and IPP in comparable concentration ranges of less
than 0.5 mg g1 which is far below dosages applied in clinical trials.
To reach dosages of 2e10 mg d1, as in the trials included in the
meta-analysis of Turpeinen et al. (2013), based on the findings for
these three tripeptides, an intake of vast amounts of dairy product
would be required. However, in previously published data from
investigation of different types of cheese, comparably low con-
centrations (e.g., 100e500 ng g1) have been detected in some
types of soft cheese, whereas still a potent in-vitro ACE inhibitory
activity of the respective cheeses has been demonstrated (Bütikofer
et al., 2007). Thus, despite the concentrations being substantially
lower than the ones applied in clinical trials, the ACE inhibitory
potential of the dairy products investigated here should not be
neglected. To date, VPP, IPP, and LPP are the best studied lacto-
peptides with ACE inhibitory activity, and have been the focus of
this study. However, several other peptides might be contained in
these dairy products and contribute (synergistically) to the anti-
hypertensive potential, but their quantities are still unknown.
Further research is therefore required to comprehensively elucidate
the antihypertensive properties of fermented dairy products. The
developedmethod here on the one hand, is useful to investigate the
content of VPP, IPP and LPP in other dairy products, and on the
other hand can be extended to the analysis of other ACE-inhibitory
peptides to get a holistic overview of contents of bioactive peptides
in our diet.
4. Conclusions
VPP, IPP, and LPP are well investigated lacto-tripeptides with
antihypertensive effects, but up to now their content in different
dairy products is understudied. In the present work, a suitable
state-of-the-art quantification method has been established and
validated, and its applicability to several dairy products was
S. Moosmang et al. / International Dairy Journal 97 (2019) 31e3938demonstrated. Quantification of these peptides in samples from
local dairies revealed only low concentrations and a contribution of
these dairy products to clinical effects can be neither derived nor
excluded from the present results. As other antihypertensive pep-
tides might be present in fermented dairy products as well, further
research is necessary to get a comprehensive view and to establish
a dose of the respective dairy products that exerts an attenuation of
blood pressure. In despite of the low detected peptide concentra-
tions, consumption of dairy products as part of a healthy and
balanced diet should be encouraged. Intake of even low amounts of
milk-derived peptides, together with peptides from other dietary
sources, might help to prevent hypertension and can contribute to
positive effects on the human cardiovascular system.
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